Diabetes and Ramadan: Practical guidelines.
Mohamed Hassanein,Monira Al-Arouj,Osama Hamdy,Wan Mohamad Wan Bebakar,Abdul Jabbar,Abdulrazzaq Al-Madani,Wasim Hanif,Nader Lessan,Abdul Basit,Khaled Tayeb,Mak Omar,Khalifa Abdallah,Abdulaziz Al Twaim,Mehmet Akif Buyukbese,Adel Abdel Aziz El-Sayed,Abdullah Bennakhi +15 more
Reads0
Chats0
TLDR
The IDF-DAR Practical Guidelines should enhance knowledge surrounding the issue of diabetes and Ramadan fasting, thereby empowering healthcare professionals to give the most up-to-date advice and the best possible support to their patients during Ramadan.About:
This article is published in Diabetes Research and Clinical Practice.The article was published on 2017-04-01 and is currently open access. It has received 247 citations till now.read more
Citations
More filters
Journal ArticleDOI
Transient increase in glucose variability during Ramadan fasting in patients with insulin-treated type 2 diabetes: A preliminary study.
TL;DR: In this article , the effect of Ramadan fasting on interstitial glucose control and variability before, during, and after Ramadan in type 2 diabetes patients receiving insulin therapy was examined, and no significant changes were observed in the average glucose level, glucose management indicator, time in range, or time in hyperglycemia at any time point.
Journal ArticleDOI
Risk stratification using the 2021 IDF-DAR risk calculator and fasting experience of Bangladeshi subjects with type 2 diabetes in Ramadan: The DAR-BAN study
A. B. M. Kamrul-Hasan,Md Shah Alam,Ahamedul Kabir,Sumon Rahman Chowdhury,Md Abdul Hannan,Emran-Ur-Rashid Chowdhury,Mainul Ahsan,Choman Abdullah Mohana,Mohammad Hasan Iftekhar,Mohammad Jahid Hasan,Samir Kumar Talukder +10 more
TL;DR: In this article , a prospective study, conducted in the peri-Ramadan period of 2022, evaluated adults with type 2 diabetes mellitus and categorized them using the IDF-DAR 2021 risk stratification tool.
References
More filters
Journal ArticleDOI
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
TL;DR: Clinical trials with the incretin mimetic exenatide and liraglutide show reductions in fasting and postprandial glucose concentrations, and haemoglobin A1c (HbA1c) associated with weight loss, but long-term clinical studies are needed to determine the benefits of targeting the inc retin axis for the treatment of type 2 diabetes.
Journal ArticleDOI
Impact of sleep debt on metabolic and endocrine function
TL;DR: Sleep debt has a harmful impact on carbohydrate metabolism and endocrine function similar to those seen in normal ageing and, therefore, sleep debt may increase the severity of age-related chronic disorders.
Journal ArticleDOI
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
TL;DR: Careful postmarketing surveillance for adverse effects, especially among the DPP4 inhibitors, and continued evaluation in longer-term studies and in clinical practice are required to determine the role of this new class of pharmacotherapies for type 2 diabetes.
Journal ArticleDOI
A Population-Based Study of Diabetes and Its Characteristics During the Fasting Month of Ramadan in 13 Countries Results of the Epidemiology of Diabetes and Ramadan 1422/2001 (EPIDIAR) study
Ibrahim Salti,Eric Bénard,Bruno Detournay,Monique Bianchi-Biscay,Corinne Le Brigand,Céline Voinet,Abdul Jabbar +6 more
TL;DR: There is a need to provide more intensive education before fasting, to disseminate guidelines, and to propose further studies assessing the impact of fasting on morbidity and mortality.
Journal ArticleDOI
Adiponectin: action, regulation and association to insulin sensitivity
TL;DR: Adiponectin in addition to possible anti‐inflammatory and anti‐atherogenic effects appears to be an insulin enhancer, with potential as a new pharmacologic treatment modality of the metabolic syndrome and type 2 diabetes.